Stocks Health care ALNY
NASDAQ · Health careAlnylam Pharmaceuticals, Inc. (ALNY)
Operating cash flow minus capital spending left $465.4M of free cash flow in fiscal 2025. At September 30, 2026 it held $1.8B in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about Alnylam Pharmaceuticals, Inc.
- Net worth
- Alnylam Pharmaceuticals, Inc. has a market value (market cap) of $20.3B at the latest share price, and shareholders' equity of $3.6B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $3.7B (+65.2% year on year), with net income of $313.7M.
- Cash flow
- In fiscal 2025 operations brought in $524.1M of cash; after $58.7M of capital spending, free cash flow was $465.4M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Alnylam Pharmaceuticals, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Alnylam Pharmaceuticals, Inc. does
Alnylam Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ALNY.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3.7B | $313.7M | $2.33 | $465.4M |
| 2024 | $2.2B | -$278.2M | -$2.18 | -$42.6M |
| 2023 | $1.8B | -$440.2M | -$3.52 | $41.9M |
| 2022 | $1B | -$1.1B | -$9.30 | -$613.3M |
| 2021 | $844.3M | -$852.8M | -$7.20 | -$718.1M |
| 2020 | $492.9M | -$858.3M | -$7.46 | -$685.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ALNY ranks in Health care
Latest SEC filings
What Alnylam Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 5, 2026
- October 30, 2026Passive stake (5% or more) SCHEDULE 13G
- October 29, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 17% to $1.5B versus the same quarter last year; diluted EPS $15.72 versus $2.14.
- October 29, 2026
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 67% to $1.3B versus the same quarter last year; diluted EPS $1.21 versus -$0.55.
- July 30, 2026
- May 27, 2026
- May 14, 2026Passive stake changed SCHEDULE 13G/A
- May 14, 2026Passive stake changed SCHEDULE 13G/A
What is ALNY worth? A DCF from its reported cash flow
Insider trades
What the people running Alnylam Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $398.9K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 2, 2026 | Supran BryanEVP, CLO and Secretary | Sold | 1,758 | $398.9K |
| September 19, 2026 | Greenstreet YvonneChief Executive Officer, Director | Received as pay | 107 | - |
| June 1, 2026 | Pyott David E IDirector | Exercised options | 3,830 | - |
| June 1, 2026 | Pyott David E IDirector | Soldpre-planned (10b5-1) | 921 | $274.2K |
| June 1, 2026 | Pyott David E IDirector | Soldpre-planned (10b5-1) | 1,175 | $351.2K |
| June 1, 2026 | Pyott David E IDirector | Soldpre-planned (10b5-1) | 1,222 | $366.4K |
| June 1, 2026 | Pyott David E IDirector | Soldpre-planned (10b5-1) | 495 | $148.9K |
| June 1, 2026 | Pyott David E IDirector | Soldpre-planned (10b5-1) | 17 | $5.1K |
Who owns ALNY
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 11% | May 6, 2026 |
| Capital World Investors13G, passive | 8.2% | May 14, 2026 |
| Capital Research Global Investors13G, passive | 7.1% | May 14, 2026 |
| Vanguard Capital Management13G, passive | 5.35% | April 29, 2026 |
| Vanguard Portfolio Management13G, passive | 5.03% | October 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 788 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 15,023,962 | +444,796 |
| Capital World Investors | 11,144,846 | +342,498 |
| BlackRock, Inc. | 10,907,675 | +462,767 |
| Capital Research Global Investors | 9,750,699 | +279,518 |
| Vanguard Portfolio Management LLC | 6,538,390 | +47,110 |
| Vanguard Capital Management LLC | 6,029,478 | +82,772 |
| Invesco Ltd. | 3,754,318 | -320,802 |
| State Street Corp | 3,555,689 | +232,991 |
| Geode Capital Management, LLC | 2,635,840 | -24,545 |
| Jpmorgan Chase & Co | 2,675,517 | -3,648,235 |
| Baillie Gifford & Co | 2,439,889 | -53,977 |
| Norges Bank | 2,271,813 | new |
| Wellington Management Group Llp | 2,110,407 | +174,482 |
| Orbis Allan Gray Ltd | 1,987,407 | +652,582 |
| Dodge & Cox | 1,955,393 | +26,140 |
| Two Sigma Investments, LP | 1,875,937 | -116,640 |
| American Century Companies Inc | 1,853,956 | +51,593 |
| Clearbridge Investments, LLC | 1,259,483 | -96,553 |
| D. E. Shaw & Co., Inc. | 1,104,109 | +45,047 |
| Morgan Stanley | 1,032,150 | +29,469 |
Insiders
16 insiders reported holding 288,666 shares in total, about $43.8M at the last price.
| Holder | Shares |
|---|---|
| Greenstreet YvonneChief Executive Officer, Director | 95,802 |
| Poulton Jeffrey V.EVP, Chief Financial Officer | 61,805 |
| Tanguler TolgaEVP, Chief Commercial Officer | 34,297 |
| Schulman Amy WDirector | 24,049 |
| Fitzgerald Kevin JosephCSO & EVP, Head of Research | 20,569 |
| Garg PushkalEVP Chief R&D | 18,693 |
| Supran BryanEVP, CLO and Secretary | 12,807 |
| McLaughlin MelissaChief Human Resources Officer | 9,443 |
| Pyott David E IDirector | 1,582 |
| Hamburg Margaret ADirector | 1,582 |
Questions about ALNY
What does Alnylam Pharmaceuticals, Inc. do?
Alnylam Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as ALNY. Its shares trade on NASDAQ under the ticker ALNY.
What is Alnylam Pharmaceuticals, Inc.'s net worth?
Alnylam Pharmaceuticals, Inc. has a market value (market cap) of $20.3B at the latest share price, and shareholders' equity of $3.6B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Alnylam Pharmaceuticals, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $2.6B.
When did Alnylam Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 5, 2026.
When is Alnylam Pharmaceuticals, Inc.'s next earnings report?
Alnylam Pharmaceuticals, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ALNY with
Follow ALNY
Get an email when Alnylam Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Alnylam Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.